Chemical Nameduvelisib
Dosage FormCapsule (oral; 15 mg, 25 mg)
Drug ClassKinase inhibitors
CompanyVerastem Inc.
Approval Year2018


  • To treat relapsed or refractory chronic or small lymphocytic leukemia after at least two prior therapies.
  • To treat relapsed or refractory follicular lymphoma after at least two prior systematic therapies.
Last updated on 12/15/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Copiktra (Duvelisib) Prescribing Information 2018Verastem Inc., Needham, MA
Document TitleYearSource
Chronic lymphocytic leukemia/small lymphocytic lymphoma, Version 4.2020. 2020NCCN Clinical Practice Guidelines in Oncology